20 articles
Discover how revolutionary drugs target 'zombie cells' that accumulate with age, potentially reversing aging and extending healthspan.
Radiation triggers a Caยฒโบ-NFATc1-Fis1 cascade that fragments mitochondria in bone marrow stem cells, halting bone repair โ and silencing Fis1 reverses it.
ProcyanidinC1, a natural senolytic, selectively eliminates senescent cells in diabetic skin, dramatically improving wound healing in mouse models.
A senolytic pairing of dasatinib and quercetin cleared senescent cells at the tendon-bone junction, dramatically improving repair strength in aged rats.
A novel class of ferroptosis inhibitors protects donor organs from ischemia-reperfusion injury, potentially saving thousands of transplant patients annually.
A novel anti-swelling hydrogel loaded with dasatinib, quercetin, and nucleus pulposus exosomes clears senescent cells and restores disc integrity in rats and goats.
Explore the molecular mechanisms of cellular senescence and how p16/p21 pathways drive SASP production, plus cutting-edge senolytic drug targets.
Single-cell sequencing reveals ferroptosis drives pulpitis; thymosin ฮฑ1 restores GPX4, cuts iron overload, and reduces inflammation in cells and rats.
A novel photoactivatable drug system uses NK immune cells to eliminate aging joint cells, reducing osteoarthritis progression in mice.
New combination therapy using stem cell exosomes and spirulina-based hydrogel shows promise for treating hard-to-heal diabetic wounds.
Breakthrough treatment uses engineered immune cells to eliminate scar tissue and restore liver function in metabolic liver disease.
New research shows GDF11 protein can prevent and treat steroid-induced bone death by activating blood vessel formation pathways.
New review reveals how plant-based compounds and stem cell therapies could eliminate aging cells and restore youthful function.
Epicrispr's GEMS platform silences disease genes epigenetically โ reversibly and safely โ with a single viral vector, targeting FSHD and beyond.
New study suggests Lilly's tirzepatide leads to more lean muscle loss compared to Novo's semaglutide, despite superior weight loss results.
A phase 2b trial finds allogeneic MSC infusions improved 6-minute walk distance by 63 meters vs placebo at 9 months in frail older adults.
Novel nanogel therapy targets mitochondrial ROS to break the inflammation-hypoxia cycle in periodontitis, showing strong preclinical results.
Master the cutting-edge molecular targets, clinical trial data, and emerging therapeutic strategies aimed at reversing ECM aging โ from senolytic combinations to biomaterial scaffolds and epigenetic reprogramming.
Novel iodide-enhanced hydrogel penetrates gum pockets to eliminate harmful bacteria while protecting regenerative stem cells.
BIIB080 failed its primary endpoint in Phase 2, yet Biogen sees potential signals worth pursuing in the fight against Alzheimer's tau tangles.
